protect cells from the effects of certain DNA-damaging drugs. FAM35A can be found in nuclear damage foci when overexpressed. It also modulates the sensitivity of BRCA1-deficient cell lines to the cytotoxic effects of campthothecin. Conserved structural elements in FAM35A are discussed, along with the degree of expression of FAM35A in cancer cases (using pre-existing data sets).
Gupta et al recently published a paper in 'Cell' identifying FAM35A as one of a number of components of a 'shieldin' complex that acts downstream of 53BP1 to modulate drug sensitivity in BRCA1-deficient cells. The Gupta study is substantially more detailed than the Tomida manuscript, although the Tomida manuscript could potentially be considered an interesting companion study. This study technically appeared first, on bioRxiv. The study certainly contains interesting findings, but is quite preliminary and short on mechanistic detail.
Major points.
1. In Figure 1C the authors co-transfect FAM35A along with RIF1 or 53BP1, and note that the exogenous proteins can be co-immunoprecipitated. This experiment is somewhat weak, because the proteins are almost certainly overexpressed. 2. Equivalently, for the experiment using GFP-FAM35A in U2OS cells described in Figure 2A , was the level of FAM35A expression in any way similar to endogenous levels? 3. Depletion of FAM35A in HEK293 cells correlated with sensitivity to MMC and etoposide, but not olaparib (Fig 2C) . This is an interesting result, but no mechanism is offered. In particular, why are cells lacking FAM35A sensitive to etoposide but not olaparib? 4. shRNA of FAM35A in BRCA1-deficient MDA-MB-436 cells altered the sensitivity of these cells to camptothecin. This is an interesting result. However, I find myself wondering what the effect was on sensitivity of these cells to MMC, etoposide and olaparib? 5. The authors suggest that FAM35A modulates resection of DNA double-strand breaks, but never attempt to measure resection. Tomida et al. have identified that FAM35A is a protein implicated in the repair of DNA double strand breaks, and have suggested a more precise role in inhibiting DNA end resection. The authors have presented data supporting FAM35A proposed role through a number of techniques, including immunoprecipitation assays, sequence analysis, immunofluorescence imaging and qPCR, and underlines the protein's significance through analysis of cancer genomic databases. The focus of this manuscript is on a novel DNA repair protein that will be of particular interest to the genomic integrity community, as well as appealing to a broader scientific audience. Overall, this is an elegant and important study that utilizes a well thought out experimental design and merits publications in EMBOJ.
Some of the findings here relate to a very recent paper published in Cell (Gupta et al. Cell 2018), and therefore the authors might want to discuss the relevance.
Minor points:
1. This manuscript suggests that FAM35A holds some affinity for ssDNA, and it would also be interesting to see what DNA substrates it prefers to bind to (or if there is any preference) and in what preference, though this might be beyond the scope of this study.
2. Does a sequence/structure analysis provide any clues to which residues are in contact with any of the proteins listed that are associated with FAM35A? 3. The paper makes claims that FAM35A is a factor as to which DNA repair pathway takes precedence. Can the authors comment as to whether the expression levels or the phosphorylation of FAM35A are cell cycle dependent?
1st Revision -authors' response 3 May 2018
Our responses and action in reply to the comments are given in italics below.
Referee #1:
The authors use an immunoprecipitation / mass spectrometry approach to identify FAM35A as a novel interacting partner for REV7. REV7 is implicated in modulating the ability of BRCA1-deficient cells to repair DNA damage. Knockdown studies of FAM35A indicate that it, too, helps protect cells from the effects of certain DNA-damaging drugs. FAM35A can be found in nuclear damage foci when overexpressed. It also modulates the sensitivity of BRCA1-deficient cell lines to the cytotoxic effects of campthothecin. Conserved structural elements in FAM35A are discussed, along with the degree of expression of FAM35A in cancer cases (using pre-existing data sets).
Gupta et al recently published a paper in 'Cell' identifying FAM35A as one of a number of components of a 'shieldin' complex that acts downstream of 53BP1 to modulate drug sensitivity in BRCA1-deficient cells. The Gupta study is substantially more detailed than the Tomida manuscript, although the Tomida manuscript could potentially be considered an interesting companion study. This study technically appeared first, on bioRxiv. The study certainly contains interesting findings, but is quite preliminary and short on mechanistic detail. Major points.
1. In Figure 1C the authors co-transfect FAM35A along with RIF1 or 53BP1, and note that the exogenous proteins can be co-immunoprecipitated. This experiment is somewhat weak, because the proteins are almost certainly overexpressed.
The purpose of the experiment in Fig 1C was 2. Equivalently, for the experiment using GFP-FAM35A in U2OS cells described in Figure 2A , was the level of FAM35A expression in any way similar to endogenous levels?
The experiments expressing FAM35A (new Figure 3A) 
in BRCA1-defective cells (see that paper's Fig. 7A). We understand that publication of further papers on this subject is imminent.
5. The authors suggest that FAM35A modulates resection of DNA double-strand breaks, but never attempt to measure resection.
This is a research area that will be stimulated by our discovery of FAM35A as a REV7-associated factor. By broadly accessing RAD51 loading, we show that resection is intact in FAM35A-defective HEK293 cells (Figure 3F), is low in a BRCA1-defective cell line, but is restored by FAM35A suppression in the BRCA1-defective cell line (Fig 5B). See the source data for Fig 5B for the best view of this.
As shown in Fig 4C, 
Referee #3:
Tomida et al. have identified that FAM35A is a protein implicated in the repair of DNA double strand breaks, and have suggested a more precise role in inhibiting DNA end resection. The authors have presented data supporting FAM35A proposed role through a number of techniques, including immunoprecipitation assays, sequence analysis, immunofluorescence imaging and qPCR, and underlines the protein's significance through analysis of cancer genomic databases. The focus of this manuscript is on a novel DNA repair protein that will be of particular interest to the genomic integrity community, as well as appealing to a broader scientific audience. Overall, this is an elegant and important study that utilizes a well thought out experimental design and merits publications in EMBOJ.
Thank you for these notes, we are also excited about the study.
Yes, this is now included towards the end of the discussion (see also comments to Referee 1).
1. This manuscript suggests that FAM35A holds some affinity for ssDNA, and it would also be interesting to see what DNA substrates it prefers to bind to (or if there is any preference) and in what preference, though this might be beyond the scope of this study. Thank you for submitting your final revised manuscript for our consideration. I have now had a chance to look through it and to assess your responses to the comments raised by the original reviewers, and found no further objections towards publication. I am therefore pleased to inform you that we have now accepted it for publication in The EMBO Journal. Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
definitions of statistical methods and measures:
a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified the exact sample size (n) for each experimental group/condition, given as a number, not a range;
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
